Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics

  • Novo Holdings and HBM Partners co-lead round with international investor syndicate
  • Numab Therapeutics to accelerate and expand clinical development of lead program into multiple cancer indications and advance pipeline of multi-specific antibodies for cancer and inflammation into clinical trials
  • Nanna Lüneborg, Partner, Novo Ventures, to join Numab Therapeutics board

Today, Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., fund and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH